

Growth hormone paediatric – initial authority application

Online PBS Authorities



Requesting PBS Authorities online provides an immediate assessment in real time.

For more information and how to access the **Online PBS Authorities** system, go to servicesaustralia.gov.au/hppbsauthorities

When to use this form

Use this form to apply for **initial** PBS-subsidised somapacitan, somatrogen or somatropin under the section 100 Growth Hormone Program for paediatric patients with severe growth hormone deficiency.

Conditions eligible for PBS-subsidised **somapacitan** or **somatrogen**:

- short stature and slow growth (SSSG)
- short stature associated with biochemical growth hormone deficiency (BGHD).

Conditions eligible for PBS-subsidised **somatropin**:

- short stature and slow growth (SSSG)
- short stature associated with biochemical growth hormone deficiency (BGHD)
- growth retardation secondary to an intracranial lesion or cranial irradiation (CL/CI)
- hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth (HO)
- neonate or infant at risk of hypoglycaemia secondary to growth hormone deficiency (N)
- biochemical growth hormone deficiency and precocious puberty (PP)
- short stature associated with Turner syndrome (TS)
- short stature due to short stature homeobox gene disorders (SHOX)
- short stature associated with chronic renal insufficiency (CR)
- short stature and poor body composition due to Prader-Willi syndrome (PW).

Important information

Initial applications to start PBS-subsidised treatment can be made in real time using the **Online PBS Authorities** system or in writing, and must include sufficient information to determine the patient's eligibility according to the PBS criteria.

Prescriptions for initial treatment should be written for a **maximum of 32 weeks** of treatment (16 weeks with up to 1 repeat).

Under no circumstances will phone approvals be granted for **initial** authority applications.

The information in this form is correct at the time of publishing and may be subject to change.

Continuing and recommencing treatment

This form is **ONLY** for **initial** treatment.

Applications for:

- continuing treatment
- change or commencement treatment
- continuing as a reclassified patient treatment, **or**
- commencement as a reclassified patient treatment

can be made in real time using the **Online PBS Authorities** system or in writing, and submitted to Services Australia for those patients who meet the criteria.

Treatment specifics

An older child is defined as:

- a male with a chronological age of **at least 12 years** or a bone age of **at least 10 years, or**
- a female with a chronological age of **at least 10 years** or a bone age of **at least 8 years**.

A younger child is defined as:

- a male with a chronological age of **less than 12 years** or a bone age of **less than 10 years, or**
- a female with a chronological age of **less than 10 years** or a bone age of **less than 8 years**.

Current data or the most recent data must not be more than **3 months** old at the time of application.

For more information

Go to servicesaustralia.gov.au/healthprofessionals

Growth hormone paediatric – initial authority application

Online PBS Authorities



You do not need to complete this form if you use the
Online PBS Authorities system.

Go to servicesaustralia.gov.au/hppbsauthorities

Patient's details

1 Medicare card number

Ref no.

or

Department of Veterans' Affairs card number

2 Family name

First given name

3 Date of birth (DD MM YYYY)

4 Biological sex

Male ☐

Female ☐

Prescriber's details

5 Prescriber number

6 Family name

First given name

7 Business phone number (including area code)

Alternative phone number (including area code)

Dosage details

8 This application is for:

☐ **somapacitan** (SSSG or BGHD only)

only one of the two strengths below is prescribed at any
given time:

of 10 mg/1.5 mL pen

or

of 15 mg/1.5 mL pen

Dose

mg/kg/week

or

☐ **somatogon** (SSSG or BGHD only)

Combination of pens requested

of 60 mg/1.2mL pen +

of 24 mg/1.2mL pen

Dose

mg/kg/week

or

☐ **somatropin**

Somatropin brand requested

Form and strength

Number of vials/cartridges requested

Dose

mg/m²/week

mg/kg/week

The mg/kg/week details are only required for Prader-Willi
patients who have reached skeletal maturity.



MCA0PB162 2607

Conditions and criteria

To qualify for PBS authority approval, the following conditions must be met.

9 The patient is being treated by a:

- ☐ specialist or consultant physician in paediatric endocrinology
- ☐ specialist or consultant in general paediatrics in consultation with a nominated specialist or consultant in paediatric endocrinology

10 The patient:

- ☐ does not have a condition with a known risk of malignancy including chromosomal abnormalities such as Down and Bloom syndromes (excluding gonadoblastoma secondary to mixed gonadal dysgenesis for short stature homeobox (SHOX) patients only)

and

- ☐ does not have an active tumour or evidence of tumour growth or activity

and

- ☐ has not previously received treatment under the PBS section 100 Growth Hormone Program

and

- ☐ is undergoing treatment for the stated indication with only one growth hormone at any given time

11 Does the patient have diabetes mellitus?

Yes ☐ **Go to 12**

No ☐ **Go to 13**

12 Does the patient have adequate diabetes control, regular screening for diabetes complications, particularly retinopathy, and growth failure that is not due to poor diabetes control?

Yes ☐ **Go to 13**

No ☐ **Ineligible**

13 Conditions

Select the condition to treat

Tick one only

- ☐ short stature and slow growth (SSSG) **Go to 14**
- ☐ short stature associated with biochemical growth hormone deficiency (BGHD) **Go to 17**
- ☐ growth retardation secondary to an intracranial lesion or cranial irradiation (CL/CI) **Go to 19**
- ☐ hypothalamic-pituitary disease secondary to a structural lesion, with hypothalamic obesity driven growth (HO) **Go to 21**
- ☐ neonate or infant at risk of hypoglycaemia secondary to growth hormone deficiency (N) **Go to 23**
- ☐ biochemical growth hormone deficiency and precocious puberty (PP) **Go to 24**
- ☐ short stature associated with Turner syndrome (TS) **Go to 25**
- ☐ short stature due to short stature homeobox (SHOX) gene disorders **Go to 26**
- ☐ short stature associated with chronic renal insufficiency (CR) **Go to 28**

- ☐ short stature and poor body composition due to Prader-Willi syndrome (PW) **Go to 29**

14 Does the patient have maturational or constitutional delay?

Yes ☐ **Go to 15**

No ☐ **Go to 16**

15 The patient is a:

- ☐ male with an estimated mature height below 160.1 cm

or

- ☐ female with an estimated mature height below 148.0 cm

16 The patient has:

- ☐ a current height at or below the 1st percentile for age and sex

and

- ☐ a growth velocity below the 25th percentile for bone age and sex measured over a 12 month interval (or a 6 month interval for an older child) **Go to 30 - Table 2**

or

- ☐ an annual growth velocity 8 cm per year or less and a bone or chronological age of 2.5 years or less

Go to 30 - Table 2

17 The patient has:

- ☐ evidence of biochemical growth hormone deficiency

and

- ☐ biochemical growth hormone deficiency is not secondary to an intracranial lesion or cranial irradiation

and a current height:

- ☐ at or below the 1st percentile for age and sex

Go to 30 - Table 1

or

- ☐ above the 1st and at or below the 25th percentiles for age and sex

Go to 18

18 The patient has:

- ☐ an annual growth velocity of 14 cm per year or less and a chronological age of 2 years or less **Go to 30 - Table 2**

or

- ☐ an annual growth velocity of 8 cm per year or less and a bone or chronological age of 2.5 years or less

Go to 30 - Table 2

or

- ☐ a growth velocity below the 25th percentile for bone age and sex measured over a 12 month interval (or a 6 month interval for an older child) **Go to 30 - Table 2**

19 The patient has:

- ☐ had an intracranial lesion and is under appropriate observation and management

or

- ☐ received cranial irradiation without having had an intracranial lesion, and is under appropriate observation and management

and

- ☐ evidence of biochemical growth hormone deficiency

and a current height:

☐ at or below the 1st percentile for age and sex

► **Go to 30 - Table 1**

or

☐ above the 1st percentile for age and sex

► **Go to 20**

20 The patient has:

☐ an annual growth velocity of 14 cm per year or less and a chronological age of 2 years or less

► **Go to 30 - Table 2**

or

☐ an annual growth velocity of 8 cm per year or less and a bone or chronological age of 2.5 years or less

► **Go to 30 - Table 2**

or

☐ a growth velocity below the 25th percentile for bone age and sex measured over a 12 month interval (or a 6 month interval for an older child)

► **Go to 30 - Table 2**

21 The patient has:

☐ a structural lesion that is not neoplastic

or

☐ a structural lesion that was neoplastic and has undergone a 12 month period of observation following completion of treatment for the structural lesion (all treatment)

Provide date of completion of **all** treatment
(DD MM YYYY)

--	--	--	--	--	--	--	--	--	--

or

☐ had a structural lesion that is neoplastic, has received medical advice that it is unsafe to treat the lesion, and has undergone a 12 month period of observation since initial diagnosis of the structural lesion

Provide the date of diagnosis (DD MM YYYY)

--	--	--	--	--	--	--	--	--	--

and

☐ evidence of biochemical growth hormone deficiency, with testing for biochemical growth hormone deficiency performed at a time when all other pituitary hormone deficits were being adequately replaced

and

☐ other hypothalamic/pituitary hormone deficits (including Adrenocorticotrophic Hormone (ACTH), Thyroid Stimulating Hormone (TSH), Gonadotropin Releasing Hormone (GnRH) and/or vasopressin/Antidiuretic Hormone (ADH) deficiencies)

and

☐ hypothalamic obesity

22 The patient has:

☐ an annual growth velocity of greater than 14 cm per year and a chronological age of 2 years or less

► **Go to 30 - Table 2**

or

☐ an annual growth velocity of greater than 8 cm per year and a bone or chronological age of 2.5 years or less

► **Go to 30 - Table 2**

or

☐ a growth velocity above the 25th percentile for bone age and sex measured over a 12 month interval (or a 6 month interval for an older child)

► **Go to 30 - Table 2**

23 The patient has:

☐ a chronological age of less than 2 years

and

☐ a documented clinical risk of hypoglycaemia

and

☐ documented evidence that the risk of hypoglycaemia is secondary to biochemical growth hormone deficiency

► **Go to 30 - Table 1**

24 The patient:

☐ is a male and commenced puberty (demonstrated by Tanner stage 2 genital or pubic hair development of testicular volumes ≥ 4 mL) before the chronological age of 9 years

or

☐ is a female and commenced puberty (demonstrated by Tanner stage 2 breast or pubic hair development) before the chronological age of 8 years

or

☐ is a female and menarche occurred before the chronological age of 10 years

and

☐ has evidence of biochemical growth hormone deficiency

and

☐ is undergoing GnRH agonist therapy for pubertal suppression

► **Go to 30 - Table 3**

25 The patient whose gender of rearing is female, has diagnostic results consistent with TS (genetically proven), defined as:

☐ a loss of whole X chromosome in all cells (45X)

or

☐ a loss of a whole X chromosome in some cells (mosaic 46XX/45X)

or

☐ genetic loss or rearrangement of an X chromosome (such as isochromosome-X, ring-chromosome, or partial deletion of an X chromosome)

► **Go to 30 - Table 3**

26 The patient has diagnostic results consistent with SHOX mutation/deletion, defined as:

☐ a karyotype confirming the presence of a SHOX mutation/deletion without the presence of mixed gonadal dysgenesis

or

☐ mixed gonadal dysgenesis (45X mosaic karyotype with the presence of any Y chromosome material and/or sex determining region Y (SRY) gene positive by Fluorescence in Situ Hybridisation (FISH) study)

and

☐ an appropriate plan of management in place for the patient's increased risk of gonadoblastoma

and

- ☐ a current height at or below the 1st percentile for age and sex

27 The patient has:

- ☐ an annual growth velocity of 14 cm per year or less and a chronological age of 2 years or less ► **Go to 30 - Table 2**

or

- ☐ an annual growth velocity of 8 cm per year or less and a bone or chronological age of 2.5 years or less
► **Go to 30 - Table 2**

or

- ☐ a growth velocity below the 25th percentile for bone age and sex measured over a 12 month interval (or a 6 month interval for an older child)

► **Go to 30 - Table 2**

28 The patient has:

- ☐ an estimated glomerular filtration rate (eGFR) < 30 mL/minute/1.73m² measured by creatine clearance, excretion of radionuclides such as diethylene triamine pentaacetic acid (DTPA), or by the height/ creatinine formula

and

- ☐ not undergone a renal transplant

or

- ☐ undergone a renal transplant and a 12 month period of observation following the transplant

Provide the date of transplant (DD MM YYYY)

--	--	--	--	--	--	--	--

and a current height:

- ☐ at or below the 1st percentile for age and sex
► **Go to 30 - Table 1**

or

- ☐ above the 1st and at or below the 25th percentiles for age and sex

and

- ☐ an annual growth velocity of 14 cm per year or less and a chronological age of 2 years or less
► **Go to 30 - Table 2**

or

- ☐ an annual growth velocity of 8 cm per year or less and a bone or chronological age of 2.5 years or less
► **Go to 30 - Table 2**

or

- ☐ a growth velocity less than or equal to the 25th percentile or less for bone age and sex measured over a 12 month interval (or a 6 month interval for an older child)

► **Go to 30 - Table 2**

29 The patient has:

- ☐ diagnostic results consistent with PW and the condition is genetically proven

or

- ☐ a clinical diagnosis of PW, confirmed by a clinical geneticist

and

- ☐ has been evaluated via polysomnography for airway obstruction and apnoea within the last 12 months

and

- ☐ has had no sleep disorders identified

or

- ☐ has had sleep disorders identified which are not of sufficient severity to require treatment

or

- ☐ has had sleep disorders identified for which the patient is currently receiving ameliorative treatment

and

- ☐ does **not** have uncontrolled morbid obesity, defined as a body weight > 200% of ideal body weight for height and sex, with ideal body weight derived by calculating the 50th percentile weight for the patient's current height

and

- ☐ has a current bone age below skeletal maturity

or

- ☐ has a current bone age at or above skeletal maturity
Skeletal maturity is a male with bone age ≥ 15.5 years of age, or a female with bone age ≥ 13.5 years of age
Date patient reached skeletal maturity (DD MM YYYY)

--	--	--	--	--	--	--	--

 ► **Go to 30 - Table 4**

30 Complete the following table(s):

Table 1 – For all BGHD, CL/CI and CR patients with a current height at or below the 1st percentile and ALL N patients

	Date (DD MM YYYY)				Height (cm)	Weight (kg)
Recent data						

'N' category ► **Go to 32**

All other categories ► **Go to 31**

Table 2 – For all BGHD, CL/CI and CR patients with a current height above the 1st percentile, and ALL SSSG, SHOX and H0 patients

	Date (DD MM YYYY)				Height (cm)	Weight (kg)
All patients – recent data						
Older child only – 6 month data						
Younger child only – 12 month data						

All categories ► **Go to 31**

Table 3 – TS and PP patients

	Date (DD MM YYYY)				Height (cm)	Weight (kg)
All patients – recent data						
All patients – 6 month data						
Younger child only – 12 month data						

► **Go to 31**

Table 4 – PW patients

	Date (DD MM YYYY)				Height (cm)	Weight (kg)	Waist circumference (cm)
Recent data							
6 month data							

► **Go to 32**

31 Provide the following:

A bone age result performed within the last 12 months, if the patient's current chronological age is > 2.5 years.

years months

Date (DD MM YYYY)

Checklist

32  The relevant attachments need to be provided with this form.

- ☐ Details of the proposed prescription(s).
- ☐ Evidence of biochemical growth hormone deficiency including the type of tests performed and peak growth hormone concentrations (if applicable).

Privacy notice

33 Personal information is protected by law (including the *Privacy Act 1988*) and is collected by Services Australia for the purposes of assessing and processing this authority application.

Personal information may be used by Services Australia, or given to other parties where the individual has agreed to this, or where it is required or authorised by law (including for the purpose of research or conducting investigations).

More information about the way in which Services Australia manages personal information, including our privacy policy, can be found at servicessaustralia.gov.au/privacypolicy

Prescriber's declaration

You do not need to **sign** the declaration if you complete this form using Adobe Acrobat Reader and return this form through Health Professional Online Services (HPOS) at servicessaustralia.gov.au/hpos

34 I declare that:

- I am aware that this patient must meet the criteria listed in the current Schedule of Pharmaceutical Benefits to be eligible for this medicine
- I have informed the patient that their personal information (including health information) will be disclosed to Services Australia for the purposes of assessing and processing this authority application
- I have provided details of the proposed prescription(s) and the relevant attachments as specified in the Pharmaceutical Benefits Scheme restriction
- the information I have provided in this form is complete and correct.

I understand that:

- giving false or misleading information is a serious offence.

☐ I have read, understood and agree to the above.

Date (DD MM YYYY) (you **must** date this declaration)

--	--	--	--	--	--	--	--	--	--

Prescriber's signature (**only** required if returning by post)



Returning this form

Return this form, details of the proposed prescription(s) and any relevant attachments:

- **online** (no signature required), upload through HPOS at servicessaustralia.gov.au/hpos
- by post (signature required) to
Services Australia
Complex Drugs Programs
Reply Paid 9826
HOBART TAS 7001